NCT03689699 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03689699
Title	Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Recruitment	Active, not recruiting
Gender	male
Phase	Phase II
Variant Requirements	No
Sponsors	Charles G. Drake
Indications	prostate cancer
Therapies	BMS-986253 + Degarelix + Nivolumab Degarelix + Nivolumab
Age Groups:	adult
Covered Countries	USA

Filter rows:

Showing 1 to 4 of 4 entries

Facility	City	State	Zip	Country	Details
Columbia University Irving Medical Center	New York	New York	10032	United States	Details
Sidney Kimmel Cancer Center- Thomas Jefferson University	Philadelphia	Pennsylvania	19107	United States	Details
Weill Cornell Medical Center	New York	New York	10021	United States	Details
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	United States	Details

Showing 1 to 4 of 4 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03689699Clinical Trial Detail